Thus, our findings suggest an effective strategy to prevent and/or treat liver inflammatory diseases by modulating the AMPK/SIRT1 pathway and targeting the XBP1/NLRP3 activity in macrophages using genetically modified MSC approaches or pharmacological interventions. The gene discussed is NLRP3; the disease is liver disorder.